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Eligibility and subsequent burden of cardiovascular disease 
of four strategies for blood pressure-lowering treatment: 
a retrospective cohort study 
Emily Herrett, Sarah Gadd, Rod Jackson, Krishnan Bhaskaran, Elizabeth Williamson, Tjeerd van Staa, Reecha Sofat, Adam Timmis, Liam Smeeth
Summary
Background Worldwide treatment recommendations for lowering blood pressure continue to be guided predominantly 
by blood pressure thresholds, despite strong evidence that the benefits of blood pressure reduction are observed 
in patients across the blood pressure spectrum. In this study, we aimed to investigate the implications of alternative 
strategies for offering blood pressure treatment, using the UK as an illustrative example.
Methods We did a retrospective cohort study in primary care patients aged 30–79 years without cardiovascular 
disease, using data from the UK’s Clinical Practice Research Datalink linked to Hospital Episode Statistics and 
Office for National Statistics mortality. We assessed and compared four different strategies to determine eligibility 
for treatment: using 2011 UK National Institute for Health and Care Excellence (NICE) guideline, or proposed 2019 
NICE guideline, or blood pressure alone (threshold ≥140/90 mm Hg), or predicted 10-year cardiovascular risk alone 
(QRISK2 score ≥10%). Patients were followed up until the earliest occurrence of a cardiovascular disease diagnosis, 
death, or end of follow-up period (March 31, 2016). For each strategy, we estimated the proportion of patients eligible 
for treatment and number of cardiovascular events that could be prevented with treatment. We then estimated 
eligibility and number of events that would occur during 10 years in the UK general population.
Findings Between Jan 1, 2011, and March 31, 2016, 1 222 670 patients in the cohort were followed up for a median of 
4·3 years (IQR 2·5–5·2). 271 963 (22·2%) patients were eligible for treatment under the 2011 NICE guideline, 
327 429 (26·8%) under the proposed 2019 NICE guideline, 481 859 (39·4%) on the basis of a blood pressure threshold 
of 140/90 mm Hg or higher, and 357 840 (29·3%) on the basis of a QRISK2 threshold of 10% or higher. During 
follow-up, 32 183 patients were diagnosed with cardiovascular disease (overall rate 7·1 per 1000 person-years, 95% CI 
7·0–7·2). Cardiovascular event rates in patients eligible for each strategy were 15·2 per 1000 person-years (95% CI 
15·0–15·5) under the 2011 NICE guideline, 14·9 (14·7–15·1) under the proposed 2019 NICE guideline, 
11·4 (11·3–11·6) with blood pressure threshold alone, and 16·9 (16·7–17·1) with QRISK2 threshold alone. Scaled to 
the UK population, we estimated that 233 152 events would be avoided under the 2011 NICE guideline (28 patients 
needed to treat for 10 years to avoid one event), 270 233 under the 2019 NICE guideline (29 patients), 301 523 using a 
blood pressure threshold (38 patients), and 322 921 using QRISK2 threshold (27 patients).
Interpretation A cardiovascular risk-based strategy (QRISK2 ≥10%) could prevent over a third more cardiovascular 
disease events than the 2011 NICE guideline and a fifth more than the 2019 NICE guideline, with similar efficiency 
regarding number treated per event avoided.
Funding National Institute for Health Research.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
Randomised trials1,2 have shown that blood pressure 
reductions, whether by diet, lifestyle, or drug therapy, 
can reduce the risk of cardiovascular disease. A reduction 
in systolic blood pressure of 10 mm Hg can reduce the 
incidence of stroke by roughly 40% and myocardial 
infarction by roughly 20%.1 Globally, most blood pressure 
treatment recommendations are based on blood pressure 
levels.3–5
In the UK, guidance4 from the National Institute for 
Health and Care Excellence (NICE) recommends that 
clinicians consider pharmacological intervention for 
primary prevention of cardiovascular disease when a 
patient’s clinic blood pressure is between 140/90 and 
159/99 mm Hg and they have one or more of the 
following: an absolute 10-year cardiovascular risk of 
20% or higher (proposed 2019 NICE guideline6 lowers 
this to ≥10%), diabetes, kidney disease, or target organ 
damage. Blood pressure lowering with pharmacological 
intervention is not recommended for patients with blood 
pressure lower than 140/90 mm Hg, even if their cardio-
vascular risk is high, whereas patients with blood 
pressure of 160/100 mm Hg or higher are recommended 
for treatment even when cardiovascular disease risk is 
low. Similarly, the 2018 European guidelines5 suggest 
treatment when a patient has stage 1 hypertension 
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(140–159/90–99 mm Hg) and has one of more of the 
following: high 10-year risk of cardiovascular disease 
mortality (on the basis of the Systematic Coronary Risk 
Evaluation system [SCORE]), renal disease, target organ 
damage, or blood pressure that is not controlled after 
3–6 months of lifestyle intervention. The guidelines3 of 
the American College of Cardiology and American Heart 
Association (ACC/AHA) have a blood pressure threshold 
for treatment of 130–139/80–89 mm Hg if the estimated 
10-year cardiovascular risk (based on the ACC/AHA 
pooled cohort equations) is 10% or higher. All patients 
with blood pressure 140–90 mm Hg or higher are eligible 
for blood pressure-lowering medication, with a target 
blood pressure of 130/80 mm Hg.
However, strong evidence suggests that using a blood 
pressure threshold to make treatment decisions might not 
be the optimal strategy. Meta-analyses of randomised and 
non-randomised studies1,7 have shown that treating patients 
with blood pressures as low as 110/70 mm Hg (lower than 
the NICE and European Society of Cardiology guideline 
threshold of 140/90 mm Hg) can reduce cardiovascular 
risk. Additionally, the absolute treatment benefit of blood 
pressure-lowering drugs is determined by a patient’s 
absolute cardiovascular risk, with more benefit achieved 
in patients with the highest risk, even when blood 
pressure is lower than treatment thresholds.8 Blood 
pressure is just one component of absolute cardiovascular 
risk, meaning that patients with blood pressure lower 
than guideline treatment thresholds could have very high 
risk, and patients with blood pressure higher than those 
thresholds could be at low risk.9 This suggests that 
many patients who might benefit from blood pressure-
lowering treatment are missing out, whereas others might 
be overtreated.
Two key considerations in determining the optimal 
strategy for blood pressure-lowering treatment are the 
number of patients who would be eligible for treatment 
and the degree to which treatment is prioritised to those 
people most likely to have future cardiovascular disease. 
The 2011 NICE guidelines4 and their proposed 2019 
update6 are positioned between two strategies: blood 
pressure-only treatment and risk-based treatment.
Before the 2011 NICE guidance, treatment recom-
mendations were based solely on blood pressure 
thresholds, treating patients with hypertension. Some 
evidence exists that general practitioners continue to 
use a blood pressure threshold of 140/90 mm Hg to 
guide treatment decisions.10 However, the aim of lowering 
blood pressure is to reduce cardiovascular risk. A 
rational strategy to determine who to treat would be to 
target patients at high cardiovascular risk rather than only 
those with hypertension. Such a strategy would involve 
Research in context
Evidence before this study
Strong evidence has shown that the benefits of blood pressure 
reduction are observed in patients across the blood pressure 
spectrum and that the absolute benefits of treatment are 
proportional to a patient’s pretreament absolute cardiovascular 
risk. However, blood pressure treatment guidelines worldwide 
continue to be guided predominantly by blood pressure 
thresholds and the concept of hypertension. We searched 
PubMed for studies published in English from Feb 11, 2009, 
to Feb 11, 2019, that compared a risk-based approach to blood 
pressure treatment with either a blood pressure-only approach 
or a combination approach (using both blood pressure and risk 
to determine treatment, as set out in US, UK, and European 
guidelines). For this search, we used the terms “blood pressure 
lowering OR blood pressure treatment OR antihypertensive*” 
AND “strateg* OR approach OR policy” AND “compare OR 
contrast” AND “cardiovascular risk OR cardiovascular disease 
risk OR absolute risk OR QRISK2”. The search generated 
228 studies, of which five were relevant; three showed the 
superiority of a risk-based approach over an entirely blood 
pressure-based approach. Two studies from low-income and 
middle-income countries additionally investigated 
combination approaches: both showed that a risk-based 
approach was superior to both a blood pressure only and 
a combination approach. All studies used trial populations or 
simulated data to compare strategies. Therefore, the potential 
effect of using a risk-based approach to determine treatment 
eligibility and subsequent cardiovascular disease burden in a 
real-life population was unclear.
Added value of this study
Using the UK as an illustrative population, our study showed 
that determining eligibility for blood pressure treatment with 
an absolute cardiovascular risk cutoff of 10% or higher (based 
on QRISK2) would increase the proportion of people who were 
eligible for treatment by 32%, compared with that of the 
2011 National Institute for Health and Care Excellence (NICE) 
UK guideline. This QRISK2-based strategy would prevent over a 
third more cardiovascular disease events than would the 
2011 NICE guideline, with the same efficiency, and would also 
prevent a fifth more events than the proposed 2019 NICE 
guideline, with similar or better efficiency. Over 10 years, 
we estimated that an absolute risk-based guideline could 
prevent nearly 90 000 more cardiovascular events in the UK 
than the 2011 NICE guideline that is currently in use.
Implications of all the available evidence
Our analyses and the evidence to date illustrate that the 
potential benefits of an absolute risk-based approach to 
assess eligibility for blood pressure-lowering treatment 
surpass those of approaches recommended by international 
guidelines. These findings show the need to re-assess blood 
pressure treatment guidelines that are based on blood 
pressure cutoffs. 
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the use of a validated cardiovascular risk score (such as 
QRISK2,11 SCORE,12 or the ACC/AHA pooled equations,13 
calculated on the basis of blood pressure and other cardio-
vascular risk factors) to determine treatment eligibility. 
This approach has been adopted for lipid lowering 
in the UK: patients whose absolute QRISK2 10-year 
cardiovascular risk is 10% or higher are recom mended 
for treatment.14
In our study, we investigated how these alternative 
strategies would affect eligibility for blood pressure-
lowering treatment in the UK. Our aim was to describe 
and compare eligibility for blood pressure-lowering 
treatment of four different strategies, relate this to sub-
sequent cardiovascular disease burden, and estimate the 
efficiency of each strategy on the basis of the number 
treated over 10 years to avoid a cardiovascular disease 
diagnosis.
Methods
Study design and participants
We did a retrospective cohort study using data from the 
UK’s Clinical Practice Research Datalink (CPRD) linked 
to Hospital Episode Statistics (HES) and mortality 
data from the Office for National Statistics (ONS). The 
CPRD is a primary care database containing anonymised 
data from approximately 6·9% of the UK population.15,16 
Data from CPRD include diagnoses, tests, clinical 
measurements, prescriptions, and specialist referrals. 
EH had full access to the CPRD database to create the 
study population. Approval was given from the CPRD’s 
Independent Scientific Advisory Committee (17_146). 
The database is broadly representative of the UK popu-
lation in terms of age and sex, with a slightly lower 
proportion of patients from younger age groups and 
from the north of England than that of the whole UK 
population.15 HES holds data on diagnoses made and 
procedures done in English hospitals, and the ONS 
mortality data hold the date and cause of deaths registered 
in England and Wales.
Participants were aged 30–79 years and registered 
with a participating CPRD practice (appendix p 11) on 
Jan 1, 2011, chosen as a start date to allow follow-up for up 
to 5 years. Few patients younger than 30 years would 
meet treatment eligibility criteria for any strategy, and 
those aged 80 years or older required careful consideration 
and are treated differently than younger patients in the 
2011 guidance.4 Patients were excluded if, at enrolment in 
the cohort, they had less than 1 year of follow-up, were 
pregnant, had an existing diagnosis of cardiovascular 
disease (recorded in CPRD or HES; appendix p 19), or 
had a last blood pressure reading taken more than 5 years 
before enrolment. We did not exclude patients with 
contra indications to any specific blood pressure-lowering 
drug. Cohort size was determined by the number 
of patients in the CPRD who met the inclusion criteria. 
The study protocol was approved by the London School of 
Hygiene & Tropical Medicine (14334). 
Procedures
We investigated four strategies to define treatment 
(panel), with eligibility based on the following: first, 
blood pressure of 140/90 mm Hg or higher alone; 
second, 2011 NICE guidelines;4 third, proposed 2019 
NICE guidelines;6 and fourth, absolute QRISK2 10-year 
cardio vascular risk score of 10% or higher alone. QRISK2 
was calculated with the algorithms supplied online and 
Read codes from the Quality and Outcomes Framework.19 
Mirroring the QRISK2 algorithm in clinical practice, 
our algorithm used a population-average imputation 
approach to ac count for missing data. Target organ 
damage was defined in the CPRD with Read codes 
recorded before the cohort start date.
Patients were followed up from Jan 1, 2011, and were 
categorised as eligible or ineligible for blood pressure-
lowering treatment under the four different strategies 
(panel). Patients were followed up until the earliest 
occurrence of a cardiovascular disease diagnosis (primary 
outcome), death, or end of CPRD follow-up or until 
March 31, 2016 (the last available date when linked data 
from HES were accessible).
A cardiovascular disease diagnosis was defined as 
the following: any record of coronary heart disease 
(myocardial infarction, angina, revascularisation pro ce-
dures, or coronary heart disease not otherwise specified) See Online for appendix
Panel: Four strategies to assess eligibility for blood pressure-lowering treatment
Blood pressure threshold alone
Patients were eligible if they either had a blood pressure of 140/90 mm Hg or higher in 
the last measurement before enrolment or were using blood pressure-lowering 
medication at enrolment and had one of the following: two previous blood pressure 
measures of 140/90 mm Hg or higher within a 3-month period,17,18 a hypertension 
diagnosis, or a flag on the general practice hypertension register.  
2011 National Institute for Health and Care Excellence (NICE) guideline4
Patients were eligible if they either met the criteria for the blood pressure strategy plus 
one or more of target organ damage,* QRISK2 score of 20% or higher, renal disease, 
or diabetes; were using blood pressure-lowering medication at enrolment and had 
two previous blood pressure measures of 160/100 mm Hg or higher within a 3-month 
period, a diagnostic code for stage 2 hypertension, or severe hypertension; or had blood 
pressure of 160/100 mm Hg or higher in the last measurement before enrolment.
Proposed 2019 NICE guideline
Patients were eligible if they either met the criteria for the blood pressure strategy plus 
one or more of target organ damage,* QRISK2 score of 10% or higher, renal disease, 
or diabetes; were using blood pressure-lowering medication at enrolment and had 
two previous blood pressure measures of 160/100 mm Hg or higher within a 3-month 
period, a diagnostic code for stage 2 hypertension, or severe hypertension; or had blood 
pressure of 160/100 mm Hg or higher in the last measurement before enrolment.
QRISK2 threshold alone
Patients were eligible if they had a QRISK2† score of 10% or higher at enrolment.
*Target organ damage includes hypertensive retinopathy, heart failure, and proteinuria (appendix). †QRISK2 includes age, sex, 
ethnicity, blood pressure, deprivation score from linked data, diabetes, family history of coronary heart disease, atrial 
fibrillation, chronic kidney disease stage 4 or 5, cholesterol–high-density lipoprotein ratio, rheumatoid arthritis, use of blood 
pressure-lowering drugs, body-mass index, and smoking status.  
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or cerebrovascular disease (stroke [not including haemor-
rhagic stroke because this is not included in QRISK2 
outcomes],11 transient ischaemic attack, or non-stroke 
cerebrovascular disease). These outcomes included any 
record from CPRD, HES, or ONS, and were defined 
according to Read codes and the codes of the International 
Classification of Diseases, tenth edition (appendix p 19). 
The primary analysis estimated the proportion of patients 
who would be eligible for treatment under each strategy, 
as well as the rate and proportion of cardiovascular 
disease events that occurred during follow-up, stratified 
by eligibility.
Statistical analysis
For each strategy, we assessed eligibility for treatment 
at enrolment and compared the number, demo graphic 
characteristics, and risk factor profiles of eligible patients. 
These numbers were then used to estimate eligibility in 
the 2011 UK population (on the basis of the national 
census).20 Under each strategy, we calculated the total 
number of patients diagnosed with cardiovascular disease 
and the overall crude rate of cardiovascular disease 
among patients eligible and ineligible for treatment. This 
was extrapolated to calculate the number of events that 
would occur during 10 years of follow-up in the UK 
population.
We estimated the number of patients needed to treat 
(NNT) to avoid an event to compare the efficiency of each 
strategy. For each strategy, NNT was calculated as the 
number of patients eligible for treatment divided by the 
number of events avoided if all eligible patients were 
treated for 10 years, assuming a 20% reduction in risk 
in treated patients (appendix p 2).
We did secondary analysis to further investigate the 
predictive ability of blood pressure and QRISK2 for 
subsequent cardiovascular disease. Each category was 
split into the following standard groups: systolic blood 
pressure at enrolment (<110, 110–119, 120–139, 140–159, 
160–179, or ≥180 mm Hg), diastolic blood pressure at 
enrolment (<70, 70–79, 80–89, 90–99, 100–109, or 
≥110 mm Hg), and QRISK2 at enrolment (<10%, 10–19%, 
20–29%, or ≥30%). Systolic blood pressure, diastolic 
 Whole cohort Blood pressure 
threshold
2011 NICE 
guideline
Proposed 2019 NICE 
guideline
QRISK2 10-year risk 
threshold
Number of patients eligible 1 222 670 (100·0%) 481 859 (39·4%) 271 963 (22·2%) 327 429 (26·8%) 357 840 (29·3%)
Follow-up time, median (IQR; years) 4·3 (2·5–5·2) 4·3 (2·5–5·2) 4·2 (2·5–5·2) 4·2 (2·5–5·2) 3·9 (2·4–5·2)
Sex
Men 530 618 (43·4%) 242 423 (50·3%) 134 958 (49·6%) 168 143 (51·4%) 209 882 (58·7%)
Women 692 052 (56·6%) 239 436 (49·7%) 137 005 (50·4%) 159 286 (48·6%) 147 958 (41·3%)
Age (years)*
30–39 251 294 (20·6%) 38 399 (8·0%) 9270 (3·4%) 9293 (2·8%) 709 (0·2%)
40–49 317 280 (25·9%) 86 909 (18·0%) 31 623 (11·6%) 32 737 (10·0%) 9397 (2·6%)
50–59 281 786 (23·0%) 121 185 (25·1%) 58 146 (21·4%) 69 414 (21·2%) 55 263 (15·4%)
60–69 238 774 (19·5%) 139 937 (29·0%) 87 968 (32·3%) 120 577 (36·8%) 159 184 (44·5%)
70–79 133 536 (10·9%) 95 429 (19·8%) 84 956 (31·2%) 95 408 (29·1%) 133 287 (37·2%)
QRISK2 risk score
<10% 864 830 (70·7%) 235 788 (48·9%) 81 358 (29·9%) 81 358 (24·8%) 0
10–19% 216 349 (17·7%) 136 578 (28·3%) 81 112 (29·8%) 136 578 (41·7%) 216 349 (60·5%)
20–29% 95 167 (7·8%) 71 019 (14·7%) 71 019 (26·1%) 71 019 (21·7%) 95 167 (26·6%)
≥30% 46 324 (3·8%) 38 474 (8·0%) 38 474 (14·1%) 38 474 (11·8%) 46 324 (12·9%)
Systolic blood pressure (mm Hg)*
<110 100 345 (8·2%) 2876 (0·6%) 2348 (0·9%) 2489 (0·8%) 6660 (1·9%)
110–119 187 402 (15·3%) 13 123 (2·7%) 9929 (3·7%) 10 610 (3·2%) 21 811 (6·1%)
120–139 603 024 (49·3%) 133 961 (27·8%) 92 186 (33·9%) 100 308 (30·6%) 162 640 (45·5%)
140–159 289 745 (23·7%) 289 745 (60·1%) 125 346 (46·1%) 171 868 (52·5%) 139 895 (39·1%)
160–179 35 618 (2·9%) 35 618 (7·4%) 35 618 (13·1%) 35 618 (10·9%) 21 939 (6·1%)
≥180 6536 (0·5%) 6536 (1·4%) 6536 (2·4%) 6536 (2·0%) 4895 (1·4%)
Systolic blood pressure (mm Hg)* 129·2 (15·6) 141·9 (12·9) 142·4 (15·6) 142·5 (14·6) 137·5 (14·8)
Diastolic blood pressure (mm Hg)* 78·2 (9·5) 83·4 (9·5) 82·5 (10·7) 82·5 (10·2) 79·3 (9·3)
Patients using blood pressure-lowering 
drugs
223 465 (18·3%) 213 046 (44·2%) 190 401 (70·0%) 200 214 (61·1%) 153 586 (42·9%)
Data are n (%) or mean (SD), unless otherwise specified. Characteristics of patients of the whole cohort and patients eligible for treatment under each strategy: blood pressure 
threshold of 140/90 mm Hg or higher, 2011 NICE guideline, proposed 2019 NICE guideline, and QRISK2 10-year risk of 10% or higher. NICE=National Institute for Health and 
Care Excellence. *Closest measure before enrolment on Jan 1, 2011. 
Table 1: Demographic and risk factor characteristics of patients at enrolment
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blood pressure, and QRISK2 10-year risk score were also 
split into quintile groups. In each group, the rate and 
proportion of cardiovascular disease events were calcu-
lated and compared across treatment strategies.
To maximise comparability between strategies, we 
stratified rates of cardiovascular disease according to use 
of blood pressure-lowering treatment at enrolment (on 
the basis of an issued prescription at enrolment) and 
whether their blood pressures were higher or lower than 
140/90 mm Hg. Treated systolic blood pressures at 
enrolment were also plotted.
We did three post-hoc sensitivity analyses. We calculated 
NNT for 5 years to prevent one cardiovascular event to 
assess whether extrapolation of our rates to 10 years 
was an acceptable approach. We assessed the primary 
outcome restricted to acute events (myocardial infarction 
and stroke). Lastly, we assessed the rate of haemorrhagic 
stroke by eligibility for each strategy. QRISK2 does not 
include haemorrhagic stroke, an important outcome 
when considering blood pressure treatment.
All analyses were done with Stata (version 14). 
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had final 
responsibility for the decision to submit for publication.
Results 
Between Jan 1, 2011, and March 31, 2016, 1 222 670 patients 
in the cohort were followed up for a median of 4·3 years 
(IQR 2·5–5·2; total follow-up 4·5 million person-years). 
During follow-up, 32 183 patients were diagnosed with 
cardiovascular disease (overall rate 7·1 per 1000 person-
years, 95% CI 7·0–7·2). Median age at entry was 51 years 
(IQR 41–62). Cohort demographic and risk factor charac-
teristics are shown for the total cohort and by eligibility 
for each strategy in table 1 and the appendix (pp 4–5).
Of the 1 222 670 patients in the cohort, 271 963 (22·2%) 
were eligible for treatment at cohort entry under the 
2011 NICE guideline, 327 429 (26·8%) were eligible 
under the proposed 2019 NICE guideline, 481 859 (39·4%) 
were eligible on the basis of blood pressure alone 
(treating those with hypertension), and 357 840 (29·3%) 
were eligible on the basis of a QRISK2 10-year risk of 10% 
or higher (figure 1, table 1). For the strategy based on 
blood pressure alone, we found a 17·2% increase in 
eligibility compared with that for the strategy based on 
the 2011 NICE guideline (appendix p 6); for the QRISK2 
strategy, we found a 7·0% net increase in eligibility, with 
some patients gaining (13·7% of the cohort) and others 
losing eligibility (6·7%) compared with that of the 2011 
NICE guideline. The proposed 2019 NICE guideline 
resulted in 4·5% additional eligible patients compared 
with the 2011 NICE guideline, with no patients losing 
eligibility under this strategy. The overlap in eligibility 
between the 2011 NICE guideline, blood pressure alone, 
and QRISK2 strategies are shown in figure 2. A com-
parison between blood pressure alone, QRISK2, and 
the 2019 NICE guideline and a breakdown of treatment 
according to eligibility are shown in the appendix (p 12).
We assessed how eligibility for treatment changed from 
the 2011 NICE guideline to the QRISK2 strategy: patients 
who lost eligibility with QRISK2 tended to be younger and 
had fewer cardiovascular risk factors (were more often 
non-smokers and had lower systolic blood pressures, and 
fewer patients had diabetes; appendix p 8). 61·4% of 
patients who lost eligibility were using blood pressure-
lowering medication at enrolment.
Of the 32 183 cardiovascular events that occurred 
during follow-up, 15 136 (47·0%) were in patients eligible 
Figure 1: Proportion of patients who were eligible for blood pressure-lowering treatment under four 
strategies versus the proportion of all subsequent cardiovascular disease events that occurred among 
eligible patients in the cohort
The four strategies are the following: blood pressure threshold of 140/90 mm Hg or higher, 2011 NICE guideline, 
proposed 2019 NICE guideline, and QRISK2 10-year risk of 10% or higher. NICE=National Institute for Health and 
Care Excellence.
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Figure 2: Eligibility of patients for blood pressure-lowering treatment based 
on three strategies
The three strategies are the following: blood pressure threshold of 140/90 mm Hg 
or higher, 2011 NICE guideline, and QRISK2 10-year risk of 10% or higher. 
NICE=National Institute for Health and Care Excellence.
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under the 2011 NICE guideline, 17 899 (55·6%) under 
the proposed 2019 NICE guideline, 20 388 (63·4%) 
under a blood pressure alone strategy, and 21 851 (67·9%) 
under the QRISK2 strategy (figure 1, appendix p 12). 
Rates of cardio vascular disease were highest in patients 
eligible under the QRISK2 strategy (16·9 per 1000 person-
years), followed by the 2011 (15·2) and the 2019 (14·9) 
NICE guidances, and were considerably lower under the 
strategy of blood pressure alone (11·4).
Compared with the 2011 NICE guideline, eligibility 
was higher and more events would be prevented under 
all other strategies, but efficiency varied. Using blood 
pressure alone to determine treatment eligibility led to 
an additional 5 037 504 patients in the UK being eligible 
for treatment compared with the NICE 2011 strategy. We 
estimated that, over 10 years, this strategy would avoid an 
additional 68 371 cardiovascular events compared with 
the 2011 NICE strategy. Under a blood pressure alone 
strategy, more patients would be treated for 10 years per 
event avoided (NNT=38), compared with under the 2011 
NICE guideline (NNT=28; table 2). We found that more 
cardiovascular events would be avoided with the QRISK2 
strategy, along with a lower NNT, than with the 2011 
NICE guideline, making QRISK2 the most efficient 
strategy (table 2).
In the secondary analyses assessing groups of patients 
split by quintiles of QRISK2 score, systolic blood 
pressure, and diastolic blood pressure, we observed that 
the gradient of the rate of cardiovascular disease was 
steepest when the cohort was split by quintiles of QRISK2 
score (figure 3). Rates according to commonly used 
categories of QRISK2 score, systolic blood pressure, 
and diastolic blood pressure also showed that QRISK2 
score was more strongly associated with future cardio-
vascular disease events than either systolic blood 
pressure or diastolic blood pressure (appendix p 14).
In the secondary analyses, we also stratified rates of 
cardiovascular disease according to use of blood pressure-
lowering treatment at enrolment. Among patients eligible 
for treatment under the 2011 NICE guideline, 70% were 
receiving treatment at enrolment and approximately half 
of those had blood pressure lower than the target of 
140/90 mm Hg (appendix p 7). Approximately 40% of 
patients eligible under the other three strategies  were 
treated at enrolment. Among both treated and untreated 
patients, the use of QRISK2 scores of 10% or higher was 
more discriminatory than the use of the 2011 NICE 
guideline for predicting future cardiovascular burden 
(appendix p 15). The distribution of blood pressures 
among patients receiving blood pressure-lowering 
treatment at enrolment showed that the majority of 
these patients had systolic blood pressure higher than 
120 mm Hg (appendix p 16).
We did several post-hoc sensitivity analyses. We 
estimated that NNT for 5 years to prevent one event were 
Estimated eligibility 
in UK population 
aged 30–79 years 
(n=29 344 080)
Predicted outcomes 
over 10 years 
among eligible 
patients if all 
patients were 
untreated*
Events that 
could be avoided 
with treatment 
of all eligible 
patients†
Patients 
needed to treat 
for 10 years to 
avoid one 
event
Additional 
patients eligible 
compared with 
2011 NICE 
guideline
(n=6 527 112)
Additional 
events avoided 
compared with 
2011 NICE 
guideline
(n=233 152)
Blood pressure threshold 11 564 616 (39·4%) 1 507 615 301 523 38 5 037 504 (77·2%) 68 371 (29·3%)
2011 NICE guideline 6 527 112 (22·2%) 1 165 760 233 152 28 ·· ··
Proposed 2019 NICE guideline 7 858 296 (26·8%) 1 351 164 270 233 29 1 331 184 (20·4%) 37 081 (15·9%)
QRISK2 10-year risk threshold 8 588 160 (29·3%) 1 614 606 322 921 27 2 061 048 (31·6%) 89 769 (38·5%)
Data are n (%), unless otherwise specified. The four strategies compared are the following: blood pressure threshold of 140/90 mm Hg or higher, 2011 NICE guideline, 
proposed 2019 NICE guideline, and QRISK2 10-year risk of 10% or higher. NICE=National Institute for Health and Care Excellence. *Estimated as predicted outcomes in 
treated and untreated patients; predicted events in untreated patients were calculated as event rate × number of eligible patients × 10; predicted events in treated patients 
were calculated as event rate × number of eligible patients × 10 × 1·25 (inflating number of outcomes in treated patients by 20%). †20% of predicted outcomes.
Table 2:  Patients eligible for blood pressure-lowering treatment under each strategy, predicted events over 10 years, events that would be avoided 
with treatment for 10 years, patients treated for 10 years per event avoided, and additional eligible patients and events avoided of each strategy 
compared with those of the 2011 NICE guideline  
Figure 3: Quintiles of QRISK2 10-year risk score, systolic blood pressure, and diastolic blood pressure at 
enrolment versus the rate of cardiovascular disease during follow-up
Error bars are 95% CIs. Quintile values for QRISK2: (1) 0·04–0·98%, (2) 0·98–2·82%, (3) 2·82–6·61%, (4) 6·61–14·23%, 
and (5) 14·23–95·70%. Quintiles for systolic blood pressure (in mm Hg): (1) 40–116, (2) 117–125, (3) 126–132, 
(4) 133–140, and (5) 141–260. Quintiles for diastolic blood pressure (in mm Hg): (1) 20–70, (2) 71–77, (3) 78–80, 
(4) 81–86, and (5) 87–192.
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greater than those calculated at 10 years for all strategies, 
but had the same between-strategy patterns as the main 
analysis (appendix p 9). Restricting our outcome to acute 
cardiovascular disease also showed the same pattern as 
the main analysis (appendix p 10). With the 2011 NICE 
guide line, NNT for 10 years was 55 patients, with the 
proposed 2019 NICE guideline was 56, with a QRISK2 
strategy was 51, and with blood pressure alone was 74. 
The QRISK2 strategy was most discriminative in 
predicting haemorrhagic stroke, with the highest rate 
found in patients eligible under the QRISK2 strategy 
and the lowest rate in patients who were ineligible for 
treatment under the same strategy (appendix p 18).
Discussion
Our contemporary cohort study of more than 1·2 mil-
lion patients from primary care in the UK describes 
eligibility for blood pressure-lowering treatment and 
subsequent cardiovascular burden on the basis of four 
different strategies. A strategy based on blood pressure 
alone or the 2019 NICE guideline would recommend far 
more patients for treatment and would prevent more 
cardiovascular outcomes, but with less efficiency in terms 
of NNT compared with that of the 2011 NICE guide-
line. However, a strategy based on a QRISK2 10-year 
cardiovascular risk threshold of 10% (akin to statin 
guidelines in the UK) would result in a net increase 
in patients eligible for treatment compared with that of 
the 2011 NICE guideline, would prevent over a third more 
cardiovascular events, and would be at least as, or perhaps 
slightly more, efficient. In the UK, scaling up the results 
from this analysis suggested that a strategy based on 
cardiovascular risk for blood pressure-lowering treatment 
could prevent an additional 89 769 cardiovascular events 
over 10 years, with the potential for many more globally if 
guidance was based on absolute risk.
Our findings suggest that substantial numbers of at-
risk patients are being overlooked for treatment because 
guidance is too focused on blood pressure. The patients in 
our cohort who would gain eligibility under a QRISK2 
of 10% or higher (roughly 13% of all patients without 
cardiovascular disease) had a 10-year cardiovascular risk at 
least equivalent to that of patients currently eligible for 
treatment and, therefore, have as much or more to gain 
as those currently being treated. By definition, patients 
who lost eligibility under a QRISK2 strategy had a low 
QRISK2 score (<10%), and this was reflected in the lower 
cardiovascular event rates of these patients. More than 
60% of patients who would lose eligibility under a QRISK2 
strategy were using blood pressure-lowering medication 
and thus, might be overtreated by existing guidance. Our 
analysis showed that an absolute cardiovascular risk 
score is more predictive of future cardiovascular burden 
than systolic blood pressure or diastolic blood pressure. 
The 2011 NICE guideline incorporates an element of 
absolute risk by targeting patients at high risk (≥20%), 
which the proposed 2019 guidance lowers to 10% or higher, 
but only if they have blood pressure of 140/90 mm Hg or 
higher.
Large systematic reviews1,7 have shown that patients 
with high cardiovascular risk would benefit considerably 
from treatment even at blood pressures lower than 
140/90 mm Hg. A 2018 systematic review and meta-
analysis21 contradicted this finding. However, the validity 
of this review is uncertain because it included hetero-
geneous studies with very different patient characteristics 
and lengths of follow-up.22,23 The results of our study show 
the potential effect of using a risk-based approach; 
therefore, the effectiveness of blood pressure-lowering 
drugs in preventing cardiovascular disease in patients 
with blood pressures lower than 140/90 mm Hg needs to 
be assessed.
Policy makers and clinicians should use the best 
available tools to predict a patient’s subsequent risk, on 
the basis of all the available evidence. In our study, a 
QRISK2-based treatment threshold outperformed the 
2011 and 2019 NICE guidelines in predicting cardio-
vascular disease and thus, is likely to be a superior tool 
for determining treatment eligibility. Because European 
guidelines5 are similar to those of the UK in recom-
mending treatment to patients with hypertension and 
incorporating risk calculation, similar gains might be 
made by applying an entirely risk-based strategy to other 
European populations. The US guidelines3 expanded 
treatment eligibility in 2017, and a similar risk-based 
approach in the USA would reduce eligibility, but could 
also be more efficient.
Guidelines24 in New Zealand have recommended an 
absolute cardiovascular risk-based strategy for both blood 
pressure-lowering and lipid-lowering treatment for longer 
than a decade, and a similar absolute risk-based strategy 
for statins is recommended in the UK.14 Additionally, a 
growing body of international evidence8,25–31 has shown 
that a risk-based strategy is superior to a blood pressure-
based approach or a combination (blood pressure and risk) 
strategy in terms of cardiovascular disease prevention.
A risk-based strategy might also be cost-effective, with 
projected savings in an Australian study26,32 greater than 
AUD$5·4 billion. Although our study did not incorporate 
an economic analysis, our results suggest that a risk-
based approach to treatment is likely to be as cost-
effective as the 2011 or 2019 NICE guidelines.
Importantly, drug treatment for blood pressure is only 
one component for reducing cardiovascular risk overall. 
We are not implying that immediate drug treatment 
should be recommended to patients when increased 
cardiovascular risk is first identified. Non-drug measures 
to reduce risk would remain an important component of 
any strategy.
Our study has several limitations. Our analyses did 
not investigate the potential harms of changing eligibility 
for blood pressure treatment. For example, not treating 
patients who have high blood pressures but have low 
absolute risk could lead to target organ damage,33 or 
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treating patients with high risk and normal blood pres-
sure could result in harmful blood pressure reductions. 
The evidence for such harms is unclear, particularly 
among patients with diabetes and older patients.34–37
We assumed that the rate of cardiovascular disease 
occurring during follow-up (median 4·3 years) could be 
extrapolated to 10 years. Therefore, our absolute numbers 
and rates come with a degree of uncertainty, but our 
sensitivity analysis over 5 years showed that a shorter 
prediction period would lead to the same conclusion.
Restricting our cohort to patients who had a recorded 
blood pressure might have biased it towards a sicker 
population who visit their general practitioner more 
frequently. The true proportion of the UK population 
who is eligible for any strategy and the true rates of 
cardiovascular disease might therefore be lower than 
reported here. However, patients who do not visit their 
GP cannot be captured or treated under any strategy, and 
our comparisons were made in patients who can be 
reached with preventive measures in real-world clinical 
practice.
Our cohort was comprised of treated and un-
treated patients. Patients who were eligible for treatment 
under the 2011 NICE guideline were more likely to 
use blood pressure-lowering treatment, affecting the 
subsequent burden of cardiovascular disease for this 
strategy more than for other strategies. However, strati-
fication by treatment showed that QRISK2 was superior 
to the 2011 NICE guideline in both treated and untreated 
groups. Our calculation of NNT assumed that all patients 
being treated were already receiving a treatment benefit 
of 20% reduction in events. However, only half of patients 
treated had a recently measured blood pressure lower 
than the UK target of 140/90 mm Hg. This suggests that 
even treated patients could benefit from further blood 
pressure lowering. Considering that very few patients 
in our cohort had systolic blood pressure lower than 
120 mm Hg, there could be additional benefits from 
lowering systolic blood pressure below 120mm Hg.
Eligibility for each strategy was based on data collected 
in 2011. Secular trends in cardiovascular disease, risk 
factors, and treatment will affect eligibility and the rate of 
cardiovascular disease, which might be higher in our 
cohort than in a more contemporary cohort.
QRISK2 calculators are widely used in UK primary 
care. However, QRISK2 was developed on the basis of 
coronary and cerebrovascular outcomes. Other outcomes 
need to be considered in assessing a risk-based approach 
to treatment, including peripheral arterial disease, heart 
failure, and target organ damage. Our sensitivity analysis 
exploring haemorrhagic stroke showed that using 
QRISK2 to determine treatment eligibility was unlikely 
to lead to withdrawal of treatment in patients at risk of 
haemorrhagic stroke.
Our study had several strengths. Our analysis was 
based on data from UK primary care. The CPRD is 
broadly representative of the UK population and thus, we 
were able to extend our results to the UK population. 
Linkage to hospital and mortality data allowed more 
cardiovascular events to be captured than by using CPRD 
alone.38
Some error in blood pressure measurement is likely to 
exist but, importantly, this strengthens our argument for 
a risk-based strategy. Blood pressures recorded in these 
data are those on which clinicians make treatment 
decisions. If a patient has unusually raised clinic blood 
pressure measures, they might be considered for therapy 
under the current approach. Because blood pressure is 
just one component of absolute risk, its effect on absolute 
risk is small. Therefore, errors in measurement or 
out-of-date measures will have less effect on eligibility for 
treatment.
Our study shows the need for re-assessment of the 2011 
and proposed 2019 NICE blood pressure treatment 
guidelines. A cardiovascular risk-based strategy would 
align with the lipid-lowering guideline and streamline 
provision of cardiovascular disease prevention, with the 
potential to prevent more cardiovascular disease and 
with more efficiency than current guidelines. Given the 
large numbers of patients who stand to benefit from a 
change in guideline, this work should be a priority for 
public health and cardiovascular disease prevention.
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